Alnylam Pharmaceuticals Inc (ALNY) is overvalued and Royalty Pharma plc (RPRX) is overvalued.
Both trade above our estimate of their intrinsic value. ALNY is the closer of the two: -37%, against -49% for RPRX.
Values as of the 22 Sept 2026 close.
Discounting its cash flows at 7.4% (average of 3 methods) values the shares at $184.17; the price of $251.65 is 37% above that value, and 83% of that value comes from beyond year five.
Leak Score 71/100 on 9 of 12 signals
Discounting its cash flows at 7.7% (average of 3 methods) values the shares at $39.27; the price of $58.52 is 49% above that value, and 80% of that value comes from beyond year five.
Leak Score 34/100 on 7 of 12 signals
| Metric | ALNY | RPRX |
|---|---|---|
| Verdict | Overvalued | Overvalued |
| Price | $251.65 | $58.52 |
| Intrinsic value | $184.17 | $39.27 |
| Margin of safety | -37% | -49% |
| Leak Score | 71/100 (9/12) | 34/100 (7/12) |
| Market cap | $33.7B | $33.7B |
| Revenue growth, 5 years | 49.8% | 2.3% |
| Operating margin | 20.8% | 62.3% |
| Net margin | 16.8% | 32.1% |
| Return on equity | 100.7% | 12.4% |
| Debt to equity | 2.21 | 1.31 |
| P/E | 42.5x | 31.1x |
| Forward P/E | 25.0x | 10.2x |
| P/B | 24.9x | 3.8x |
| Dividend yield | — | 1.8% |